Micellar electrokinetic capillary chromatography for therapeutic drug monitoring of carbamazepine and its main metabolites.
In carbamazepine (CBZ) therapy the concomitant monitoring of concentrations of CBZ and its metabolites is strictly recommended, primarily to avoid toxic side effects. Currently, clinical routine monitoring of CBZ is accomplished by high-performance liquid chromatography or immunological methods. In this study a micellar electrokinetic capillary chromatographic (MECC) method was developed for routine drug monitoring of CBZ and its main metabolites, carbamazepine 10,11-diol and carbamazepine 10,11-epoxide, in human serum or plasma samples. The MECC method enabled baseline separation of all analytes within 2.5 min. The assay revealed sufficient precision and sensitivity and the results of either an automated HPLC or the MECC chromatography assay were in good agreement (r=-0.97). The maximum deviation for CBZ was 0.26 microM.
Department of Psychiatry, University of Mainz, Germany.
S
S
Härtter
B
B
Jensen
C
C
Hiemke
M
M
Leal
H
H
Weigmann
K
K
Unger
D000927:Anticonvulsants / Q000097:blood*; D002220:Carbamazepine / Q000031:analogs & derivatives / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D016903:Drug Monitoring / Q000379:methods*; D019075:Electrophoresis, Capillary; D006801:Humans
D000927:Anticonvulsants; D002220:Carbamazepine; C004822:10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide; C012227:carbamazepine epoxide